Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
February 16 2021 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a
biopharmaceutical company focused on discovering and developing
novel products for patients with cancer, today announced that
Steven Fruchtman, M.D., President & CEO, will present a virtual
Company update at the 2021 BIO CEO & Investor Digital
Conference being held February 16-18, 2021. Avi Oler, Senior VP,
Corporate Development, will be available for 1x1 meetings scheduled
through the Bio Partnering system.
Dr. Fruchtman’s presentation will be available
on demand during the conference, and a replay will be available
here beginning February 19.
About Onconova Therapeutics,
Inc.
Onconova Therapeutics is a biopharmaceutical
company focused on discovering and developing novel products to
treat cancer. The Company has proprietary targeted anti-cancer
agents designed to disrupt specific cellular pathways that are
important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase
inhibitor ON 123300 is currently in a dose-escalation and expansion
Phase 1 trial in China, and a dose-escalation and expansion Phase 1
trial is planned in the U.S. to commence in the first half of 2021.
Onconova’s product candidate oral rigosertib is currently in a
dose-escalation and expansion Phase 1 investigator-initiated study
targeting patients with KRAS+ lung adenocarcinoma in combination
with nivolumab. In addition, Onconova has commenced preclinical
work investigating rigosertib in COVID-19. For more information,
please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova’s expectations regarding the
registered direct offering, its patents and clinical development
plans including [patient enrollment timelines and] indications for
its product candidates. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should," "approximately" or other words
that convey uncertainty of future events or outcomes. Although
Onconova believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including the success and
timing of Onconova's clinical trials and regulatory agency and
institutional review board approvals of protocols, Onconova’s
ability to continue as a going concern, the need for additional
financing, Onconova’s collaborations, market conditions and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Contact information
Company Contact:Avi
OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
Investor Contact:LHA Investor
Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024